The antimetastatic activity of ten compoundsstructurally related to nojirimycin A was examined using a pulmonary metastatic model of mouse B16 melanoma. Nojirimycin B, deoxynojirimycin, D-gluco-(5-lactam, CP3068and CP3069 are structural analogues of nojirimycin A, and showed potent or moderate antimetastatic activities. Nojirimycin A, nojirimycin B, deoxynojirimycin and D-gluco-<5-lactam showed potent or moderate inhibitory activities against a-glucosidase, /?-glucosidase and /?-mannosidase, but CP3068 and CP3069 in which the structures were related to D-gluco-^-lactam showed no inhibitory activities.
D-gluco-<5-lactam showed potent or moderate inhibitory activities against a-glucosidase, /?-glucosidase and /?-mannosidase, but CP3068 and CP3069 in which the structures were related to D-gluco-^-lactam showed no inhibitory activities.
CP3041, CP3042, CP3043, CP3045 and CP3048 are analogues of sodium D-glucaro-cJ-lactam (ND2001), a carboxy derivative of nojirimycin A, and showed potent or moderate antimetastatic activities. But no analogue was superior to ND2001concerning with antimetastatic and anti-/?-glucuronidase activities. CP3041 and CP3042 showed potent and moderate inhibitory activities against /?-glucuronidase, respectively, but CP3043, CP3045 and CP3048 showed little or no activities.
Nojirimycin A, 5-amino-5-deoxy-D-glucose, is an antibiotic produced by several Streptomyces strains1}. It inhibits various glycosidases activities2), and mouse tumor metastases3'4).
Sodium D-glucaro-(5-lactam (ND200 1)5'6), an oxydation derivative of nojirimycin A, shows potent inhibitory activity against /?-glucuronidase7) and mouse tumor metastases6). Nojirimycin B8) and deoxynojirimy- cin9'10) are also microbial products, and exhibit anti-glycosidase activities2' 8).
A trihydroxy-pipecolic acid (CP3041), an oxidation product of deoxynojirimycin, was isolated from a plant seed11} and showed anti-/?-glucuronidase activity 1 2). The present study was undertaken to examine the antimetastatic activity of structural analogues of nojirimycin A and ND2001, and to clarify the possible relationships of the antimetastatic activity with antiglycosidases and anti-/?-glucuronidase activities.
Materials and Methods

General
Melting points were determined using a YANAKO MP-S3 micro-melting point apparatus and are uncorrected. Optical rotations were determined with a Perkin-Elmer 241 polarimeter. NMR spectra were recorded by a JEOL GX-400 instrument. Chemical shifts (5) are reported in ppm from DOH ((54.8ppm) in D2O 155 or from TMSin other solvents. Coupling constants are given in hertz. Mass spectra were measured with a Hitachi M-80B apparatus.
Preparation of Nojirimycin Derivatives
Nojirimycins A and B, deoxynojirimycin, D-gluco-^-lactam and sodium D-glucaro-<5-lactam (ND2001) (Fig. 1) were prepared in this laboratory according to the known procedures1'5'8'9^.
Nojirimycins A and B were used as bisulfite adducts.
Syntheses of CP3068 and GP3069
The synthetic pathway ofCP3.068 and CP3069 starting from (s)-(+)-6-hydroxymethyl-2-piperidinone (1) is shown in Scheme 1. Optically pure 1 was prepared according to the literature13).
A solution of 1 (10.0g, 77.5mmol) in a mixed solvent of pyridine (40ml) and methylene chloride (160ml) was cooled to -40°C and a solution of benzoyl chloride (12.9ml, 111 mmol) THF (85ml) was added in drops. After 1.5 hours, acetic acid (0.3 ml) was added under ice-cooling. The reaction mixture was stood for 1 hour, and diluted with chloroform (500ml). After washing with 5% NaHCO3 and water, followed by evaporation of solvent, the residue was subjected to column chromatographyon Wakogel C-300 (240 g). After washing with toluene, it was eluted with a mixture oftoluene -ethyl acetate 7 : 1 (v/v) to give 7V-/-butoxycarbonyl benzoyl ester (9.6 g). This compound (9.6g, 29mmol) was dissolved in dry THF (160ml) , and cooled to -78°C under nitrogen. After adding one molar solution of lithium bis (trimethylsilyl) amide in THF (35ml), the mixture was stirred at -78°C for 20 minutes, and phenylselenenyl chloride (6.1 g, 32mmol) was added. The mixture was stirred at -78°C for 40 minutes, and then was allowed to rise to room temperature. After 1 hour, acetic acid (3.8ml) was added. Purification by column chromatography on Wakogel C-300 (340g), developing with toluene-ethyl acetate 5 : 1 (v/v) gave the a, /?-unsaturated compound (6.3 g). This compound (6.3 g, 19mmol) was dissolved under ice-cooling in a mixture of trifluoroacetic acid (108 ml) and water (12ml), and stirred for 1 hour. The reaction mixture was evaporated until dry, and the residue was dissolved in chloroform (240ml). After washing and concentrating as described above, the residue was purified by column chromatography on Wakogel C-300 (350g). Development with chloroform-ethyl acetate 2 : 1 (v/v) gave the de-/-butoxycarbonyl unsaturated compound 4
(1.9g).
[a]£2 +22. 
(700mg, 1.73mmol). The mixture was stirred at 60°C for 10 minutes, cooled to 0°C, and diluted with chloroform (48 ml). After washing and concentration, the residue was purified over Wakogel C-300 (40 g), washed with toluene and developed with toluene -ethyl acetate 7 : 1 (v/v). Further purification was accomplished using a Kusano prepacked silicagel column CPS-254L-1.
Elution
with toluene-ethyl acetate 8: (570^1) and water (230/^1), and tetraethylammonium hydroxide (340 jA) was added under ice-cooling. The mixture was stirred at 0°C for 1 hour and evaporated after addition of I n HC1 (184jA). The residue was purified over Wakogel C-300 (5.7 g). Washing with chloroform and elution with chloroform -acetone A solution of CP3042 hydrochloride (lOOmg) in 15% ammonia-ethanol (8 ml) was stood at room temperature overnight, and concentrated until dry. The residue was washed with ethyl ether and dissolved in water by adding 1 n HC1. The aqueous solution (pH 3) was freeze-dried, and the residue was crystallized from H2O-MeOHEtOH to give 2(5')-amidocarbonyl-3(^),4(jR),5(5f)-trihy- To a solution of CP3041 (lOOmg, 0.56mmol) in acetonitrile (400 pS) were added butyraldehyde (101 /4, 1.13 mmol) and sodium cyanoborohydride (43 mg, 0.68 mmol), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was adjusted to pH 1 with In HC1, and acetone (200/xl) was added. The solution was stood for 2 hours, and evaporated until dry. The residue was extracted three times with ethanol (each 1 ml), and the ethanol extract was concentrated and applied to a column ofDowex 50Wx 8 (H+, 10ml). The column was washed with water (30ml), and eluted with 1 n NH4OH to give 2(S')-carbpxy-3(^),4(^),5(S')-trihydroxy-AT-butylpiperidine (CP3045, 46 mg). Tumor Cell Lines and Culture The B16 melanoma high metastatic variant (the B16 variant)6), Lewis lung carcinoma (3LL), mouse BMT-16 fibrosarcoma14) and rat SST-2 breast carcinoma15) were used. BMT-16cells were cultured on Eagle's minimal essential mediumsupplemented with 8% fetal calf serum were cultured at 37°C in a humidified 5% CO2 -95% air atmosphere.
Determination of Experimental Lung Metastasis
For experimental metastasis, a test sample was added to the culture of the B16 variant and incubated at 37°C in a humidified 5% CO2-95%air atmosphere for 72 hours. The concentration of sample was chosen in the range of noncytotoxity. The treated cells were harvested FEB. 1996 by treating with trypsin-EDTA, and washing according to the procedure described previously6). The cells were suspended in Dulbecco's phosphate-buffered saline without Ca2+ and Mg2+ at 5x105cells/ml. A 0.1ml portion of the B16 variant cell suspension was implanted iv into a female 6 week-old BDFi mouse (Japan SLC Inc.
[Shizuoka]). Three mice were used for one group except the case described especially. The mice were cared for 14 days and then pulmonary tumor colonies were counted. The percent inhibition of metastatsis was calculated from the ratio of tumor colony numbers of treated and control groups. beans; jS-glucuronidase from bovine liver. Crude enzyme solutions of tumor cells were prepared as described previously16). The cultured tumor cells were harvested, washed twice with lOmM Tris-HCl (pH 7.5) containing 0.14m NaCl and suspended in 50mM Tris-HCl (pH 7.5) containing 0.5% Triton X-100. After incubation for 5 minutes at 25°C and then 1 hour at 4°C, the suspension was centrifuged at 10,000 xg for 5 minutes at 4°C and the supernatant was used as a crude enzyme of When the inhibitory rates of metastasis of CP3068 and CP3069, thio analogues of D-gluco-<5-lactam, were comparedat the non-cytotoxic concentrations, CP3069 (10 and 30/xg/ml) showed comparable or higher rates of metastasis inhibition than CP3068 (0.3 and 1 /xg/ml). The cytotoxicity of CP3068 was reduced at least 30 times by introducing a methoxy group at C-3. Five mice were used. Ca salt was used.
Measurements of EnzymeActivities of Glycosidases
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The antimetastatic activity of CP3069was comparable to or even more potent than that ofD-gruco-<S-lactamat 10 /ig/ml.
Inhibition of Enzyme Activities by Nojirimycin A Derivatives and its Analogues Nojirimycin A, its derivatives and structural analogues showed the inhibitory activities against various glycosidases and /?-glucuronidase as shown in Table 2 .
Nojirimycin A showed potent inhibitory activity against a and /?-glucosidases, but little or no activity against a-mannosidase and^-glucuronidase.
Nojirimycin B showed the potent activity against^-glucosidase and a-mannosidase, but moderate activity against aglucosidase and no activity against^-glucuronidase. Deoxynojirimycin showed moderate activity against a-glucosidase, weak activity against jS-glucosidase and a-mannosidase, but no activity against /?-glucuronidase.
D-Gluco-(5-lactam showed moderate activity against jS-glucosidase, but little or no activity against amannosidase and /?-glucuronidase.
On the other hand, ND2001 showed no activity against three glycosidases and the most potent activity against /?-glucuronidase.
Although both CP3068 and CP3069 are analogues of D-Gluco-^-lactam, they showed no significant inhibitory activities against the glycosidases and /?-glucuronidase examined.
Glycosidase inhibitors such as castanospermine17), swainsonine17), nojirimycin A3'4), and epicyclophellitol18) have been reported to inhibit experimental pulmonary metastasis. These compoundsinduced immature carbohydrate chains on the surfaces of tumor cells by inhibiting glycosidase activity, leading to a loss of From the results in Table 2 , nojirimycin A, nojirimycin B, deoxynojirimycin, and D-gluco-^-lactam may be added in this class of antimetastatic agents. In an attempt to correlate the a-glucosidase and metastasis inhibitions, nojirimycin A showed the most potent activity in both inhibitions.
However Table 4 . CP3043, CP3045 and CP3048 showed little or no inhibitory activity against /?-glucuronidase.
All the CP compounds examined showed no significant activity against a-glucosidase, /?-glucosidase, and a-mannosidase (Table 4) . In an attempt to correlate /?-glucuronidase inhibition with the antimetastatic activity, distributions of /?-glucuronidase in mouse melanoma B16 and mouse lung carcinoma 3LL, in which metastasis was inhibited by ND20016), and in mouse flbrosarcoma BMT-ll and rat breast carcinoma SST-2, in which metastasis was not inhibited by ND20016), were examined. The B16 variant showed the highest /?-glucuronidase activity (Absorbance of phenolphthalein liberated from the substrate was 0.73 per 106 cells), followed by SST-2 (0.20), 3LL (0.03) and BMT-1 1 (0.00). These results showed that the content of /?-glucuronidase is unrelated to the antimetastatic activity. ND2001 showed potent and comparable inhibition against jS-glucuronidase of the B16 variant and SST-2. The inhibition rates to the no addition control were 69.9% and 83.6% at 0.1 /ig/ml, or 96.4% and 100% at 1^g/ml for the B16 variant and SST-2, respectively. Therefore, the potent antimetastatic activity of ND2001could not be ascribed to its potent 
